Route One Investment Company L.P. Purchases New Stake in Thermo Fisher Scientific Inc. $TMO

Route One Investment Company L.P. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 280,400 shares of the medical research company’s stock, valued at approximately $140,581,000. Thermo Fisher Scientific comprises approximately 5.6% of Route One Investment Company L.P.’s holdings, making the stock its 9th largest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the last quarter. Kilter Group LLC purchased a new position in Thermo Fisher Scientific in the second quarter valued at approximately $25,000. Allied Private Wealth LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at $26,000. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the last quarter. Finally, Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 73,493 shares of company stock valued at $43,950,381. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMO. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $627.96 on Wednesday. The stock’s 50-day simple moving average is $548.75 and its two-hundred day simple moving average is $510.05. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00. The firm has a market capitalization of $232.19 billion, a P/E ratio of 33.78, a P/E/G ratio of 2.56 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.